Type 2 diabetes

On this page

Quick Overview

Type 2 diabetes (T2DM) accounts for 90% of diabetes cases, characterized by insulin resistance and progressive β-cell dysfunction. Management focuses on HbA1c control, cardiovascular risk reduction, and preventing microvascular complications. NICE NG28 emphasizes individualized targets and early cardiovascular protection.

Core Facts & Concepts

Diagnostic Criteria

  • Fasting glucose ≥7.0 mmol/L OR random glucose ≥11.1 mmol/L
  • HbA1c ≥48 mmol/mol (6.5%) - avoid if haemoglobinopathy, pregnancy, children
  • Symptomatic: single test sufficient; asymptomatic: requires confirmation

HbA1c Targets (NICE NG28)

  • Standard: 48 mmol/mol (6.5%) - lifestyle + single drug
  • Intensified: 53 mmol/mol (7%) - on drug associated with hypoglycaemia
  • Individualize for: frailty, life expectancy <10 years, high hypoglycaemia risk

Figure 1: Retinal photograph showing dot-blot haemorrhages, hard exudates and cotton wool spots

Medication Contraindications

  • Metformin: eGFR <30 mL/min, tissue hypoxia risk (heart failure, sepsis)
  • SGLT2i: eGFR <20 mL/min, recurrent UTIs, DKA history
  • GLP-1 RA: severe gastroparesis, pancreatitis history
  • Sulfonylureas: avoid if hypoglycaemia risk (elderly, erratic eating)
  • Pioglitazone: heart failure, bladder cancer, osteoporosis risk

Problem-Solving Approach

NICE NG28 Pharmacotherapy Algorithm

  1. First-line: Metformin (titrate to 2g/day, modified-release if GI intolerance)
  2. Dual therapy if HbA1c >58 mmol/mol after 3 months:
    • CVD established or QRISK ≥10%: Add SGLT2i with proven CV benefit
    • BMI ≥35: Consider GLP-1 RA (if HbA1c ≥58 after dual therapy)
    • Otherwise: Add DPP-4i, pioglitazone, or sulfonylurea
  3. Triple therapy: Metformin + SGLT2i + third agent OR switch to insulin

Figure 2: Blood glucose meter showing reading of 3.2 mmol/L with hypoglycaemia warning

🚩 Red Flags for Insulin Initiation

  • Persistent hyperglycaemia despite triple therapy (HbA1c >75 mmol/mol)
  • Symptomatic hyperglycaemia with weight loss (exclude T1DM/LADA)
  • Acute illness, surgery, pregnancy

⚠️ Warning: SGLT2i carry DKA risk even with normal glucose ("euglycaemic DKA"). Stop during acute illness and perioperatively.

Analysis Framework

Drug ClassHbA1c ReductionWeight EffectHypo RiskCV BenefitKey Adverse Effect
Metformin10-20 mmol/molLoss/neutralNoNeutralGI upset, lactic acidosis
SGLT2i10-15 mmol/molLoss (2-3 kg)NoYesGenital infections, DKA
GLP-1 RA15-20 mmol/molLoss (3-5 kg)NoYesNausea, pancreatitis
DPP-4i10 mmol/molNeutralNoNeutralWell tolerated
Sulfonylureas15-20 mmol/molGainYesNoHypoglycaemia, weight gain
Pioglitazone10-15 mmol/molGainNoNeutralFluid retention, fractures

Cardiovascular Risk Management (as important as glycaemic control)

  • Statin: Atorvastatin 20 mg for all T2DM (primary prevention)
  • ACEi/ARB: If hypertension, albuminuria, or age >55 with CV risk factors
  • Antiplatelet: Aspirin 75 mg if CVD established (NOT primary prevention)

Visual Aid

Key Points Summary

Diagnosis: HbA1c ≥48 mmol/mol, fasting glucose ≥7.0 mmol/L (confirm if asymptomatic)

Targets: 48 mmol/mol (lifestyle + single drug), 53 mmol/mol (if hypoglycaemia risk)

First-line: Metformin 2g/day; contraindicated if eGFR <30 mL/min

CVD protection: Add SGLT2i if established CVD or QRISK ≥10% (regardless of HbA1c)

GLP-1 RA: Consider if BMI ≥35 and HbA1c >58 mmol/mol despite dual therapy

Avoid sulfonylureas: High hypoglycaemia risk in elderly, erratic eating patterns

Annual screening: Retinopathy (fundoscopy), nephropathy (ACR), neuropathy (monofilament), foot examination

📌 Remember: METFORMIN - Metformin first, EGFR check, Target individualized, Foot checks, Ophthalmology referral, Risk CV assessment, Monitor HbA1c 3-6 monthly, Insulin if triple therapy fails, Nephropathy screening (ACR)

Practice Questions: Type 2 diabetes

Test your understanding with these related questions

A 46-year-old man presents with recurrent episodes of severe flushing and diarrhea. CT shows liver metastases and a pancreatic mass. Chromogranin A is markedly elevated. What is the most likely primary tumor?

1 of 5

Flashcards: Type 2 diabetes

1/10

Pregnant patients with T1DM should monitor their glucose _____

TAP TO REVEAL ANSWER

Pregnant patients with T1DM should monitor their glucose _____

multiple times during the day

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial